High expression of a disintegrin and metalloproteinase-9 predicts a shortened survival time in completely resected stage Ⅰ non-small cell lung cancer

Zhang,Jun; Qi,Juan; Chen,Ning; Fu,Weineng; Zhou,Baosen; He,Anguang

doi:10.3892/ol.2013.1209

High expression of a disintegrin and metalloproteinase-9 predicts a shortened survival time in completely resected stage Ⅰ non-small cell lung cancer

Authors:
- Jun Zhang
- Juan Qi
- Ning Chen
- Weineng Fu
- Baosen Zhou
- Anguang He
View Affiliations

Affiliations: Department of Molecular Targeted Therapeutics, China Medical University Lung Cancer Center, The First Hospital of China Medical University, Shenyang, P.R. China
Published online on: February 22, 2013 https://doi.org/10.3892/ol.2013.1209
Pages: 1461-1466

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of this study was to investigate the abnormal expression of a disintegrin and metalloproteinase-9 (ADAM9) in human resected non-small cell lung cancer (NSCLC) tissue, in order to evaluate the significance of ADAM9 expression in surgically resected NSCLC. Sixty-four cases of completely resected stage Ⅰ NSCLC with mediastinal N2 lymph node dissection were immunohistochemically analyzed for ADAM9 protein expression. Survival, univariate and multivariate analyses were conducted to assess the significance of ADAM9 expression and its correlation with other clinicopathological characteristics. ADAM9 was observed to be significantly more highly expressed in NSCLC tissue compared with normal control lung tissue (P=0.001). The 5-year survival rate for patients with NSCLC tissues highly expressing ADAM9 was significantly lower when compared with NSCLC tissues of patients exhibiting low expression of ADAM9 (56.9 vs. 88.9%, P=0.012). Multivariate analysis identified that high expression of ADAM9 is an independent factor of shortened survival time in resected stage Ⅰ NSCLC (HR, 3.385; 95% CI, 1.224-9.360; P=0.019). These results clearly demonstrate that ADAM9 is highly expressed in NSCLC and highly expressed ADAM9 correlates with shortened survival time, suggesting that ADAM9 is a novel biomarker for predicting prognosis in resected stage Ⅰ NSCLC. ADAM9 may also become a useful predictive biomarker for the selection of adjuvant chemotherapy treatment of NSCLC.

View Figures

View References

1	Jemal A, Siegel R, Xu J and Ward E: Cancer statistics 2010. CA Cancer J Clin. 60:277–300. 2010. View Article : Google Scholar
2	Molina JR, Yang P, Cassivi SD, Schild SE and Adjei AA: Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc. 83:584–594. 2008. View Article : Google Scholar : PubMed/NCBI
3	Mountain CF: Revisions in the International System for Staging Lung Cancer. Chest. 111:1710–1717. 1997. View Article : Google Scholar : PubMed/NCBI
4	Nesbitt JC, Putnam JB Jr, Walsh GL, Roth JA and Mountain CF: Survival in early-stage non-small cell lung cancer. Ann Thorac Surg. 60:466–472. 1995. View Article : Google Scholar : PubMed/NCBI
5	Seals DF and Courtneidge SA: The ADAMs family of metalloproteases: multidomain proteins with multiple functions. Genes Dev. 17:7–30. 2003. View Article : Google Scholar : PubMed/NCBI
6	Fischer OM, Hart S, Gschwind A, Prenzel N and Ullrich A: Oxidative and osmotic stress signaling in tumor cells is mediated by ADAM proteases and heparin-binding epidermal growth factor. Mol Cell Biol. 24:5172–5183. 2004. View Article : Google Scholar : PubMed/NCBI
7	Hirao T, Nanba D, Tanaka M, Ishiguro H, Kinugasa Y, Doki Y, Yano M, Matsuura N, Monden M and Higashiyama S: Overexpression of ADAM9 enhances growth factor-mediated recycling of E-cadherin in human colon cancer cell line HT29 cells. Exp Cell Res. 312:331–339. 2006.PubMed/NCBI
8	Mahimkar RM, Visaya O, Pollock AS and Lovett DH: The disintegrin domain of ADAM9: a ligand for multiple beta1 renal integrins. Biochem J. 385:461–468. 2005. View Article : Google Scholar : PubMed/NCBI
9	O’Shea C, McKie N, Buggy Y, Duggan C, Hill AD, McDermott E, O’Higgins N and Duffy MJ: Expression of ADAM-9 mRNA and protein in human breast cancer. Int J Cancer. 105:754–761. 2003.
10	Tannapfel A, Anhalt K, Häusermann P, Sommerer F, Benicke M, Uhlmann D, Witzigmann H, Hauss J and Wittekind C: Identification of novel proteins associated with hepatocellular carcinomas using protein microarrays. J Pathol. 201:238–249. 2003. View Article : Google Scholar : PubMed/NCBI
11	Carl-McGrath S, Lendeckel U, Ebert M, Roessner A and Röcken C: The disintegrin-metalloproteinases ADAM9, ADAM12, and ADAM15 are upregulated in gastric cancer. Int J Oncol. 26:17–24. 2005.PubMed/NCBI
12	Grützmann R, Lüttges J, Sipos B, Ammerpohl O, Dobrowolski F, Alldinger I, Kersting S, Ockert D, Koch R, Kalthoff H, Schackert HK, Saeger HD, et al: ADAM9 expression in pancreatic cancer is associated with tumour type and is a prognostic factor in ductal adenocarcinoma. Br J Cancer. 90:1053–1058. 2004.
13	Fritzsche FR, Jung M, Tölle A, Wild P, Hartmann A, Wassermann K, Rabien A, Lein M, Dietel M, Pilarsky C, Calvano D, Grützmann R, et al: ADAM9 expression is a significant and independent prognostic marker of PSA relapse in prostate cancer. Eur Urol. 54:1097–1106. 2008. View Article : Google Scholar : PubMed/NCBI
14	Fritzsche FR, Wassermann K, Jung M, Tölle A, Kristiansen I, Lein M, Johannsen M, Dietel M, Jung K and Kristiansen G: ADAM9 is highly expressed in renal cell cancer and is associated with tumour progression. BMC Cancer. 8:1792008. View Article : Google Scholar
15	Zubel A, Flechtenmacher C, Edler L and Alonso A: Expression of ADAM9 in CIN3 lesions and squamous cell carcinomas of the cervix. Gynecol Oncol. 114:332–336. 2009. View Article : Google Scholar : PubMed/NCBI
16	Qi J and Zhang J: Abnormal expression of ADAM9 in non-small cell lung cancers. Zhongguo Yike Daxue Xuebao. 39:670–671. 2010.(In Chinese).
17	Zhang J, Qi J, Chen N, Guo Y, Fu W, Zhou B and He A: Highly expressed ADAM9 in completed resected stage I non-small cell lung cancer cases predicts a shortened survival. J Thorac Oncol. 6:s1068–s1069. 2011.
18	Shintani Y, Higashiyama S, Ohta M, Hirabayashi H, Yamamoto S, Yoshimasu T, Matsuda H and Matsuura N: Overexpression of ADAM9 in non-small cell lung cancer correlates with brain metastasis. Cancer Res. 64:4190–4196. 2004. View Article : Google Scholar
19	Zhang J, Ren H, Yuan P, Lang W, Zhang L and Mao L: Down-regulation of hepatoma-derived growth factor inhibits anchorage-independent growth and invasion of non-small cell lung cancer cells. Cancer Res. 66:18–23. 2006. View Article : Google Scholar : PubMed/NCBI
20	Zhang J and Mao L: SiRNA targeting hepatoma-derived growth factor (HDGF) inhibits growth of non-small cell lung cancer in xenograft models. Tumor Biology 35: Emerging Molecules, Mechanisms, and Models. Proc Amer Assoc Cancer Res. 47:abstract #5135. 2006.
21	Zhang J, Qi J, Guo Y, Guo Y, Fu W, Zhou B, Wu G, Han L and He A: Aberrant expression of HDGF and its prognostic values in surgically resected non-small cell lung cancer. Zhongguo Fei Ai Za Zhi. 211–218. 2011.(In Chinese).
22	Besse B and Le Chevalier T: Adjuvant chemotherapy for non-small-cell lung cancer: a fading effect? J Clin Oncol. 26:5014–5017. 2008. View Article : Google Scholar : PubMed/NCBI
23	Douillard JY and Gauducheau CR: Adjuvant chemotherapy for non-small-cell lung cancer: it does not always fade with time. J Clin Oncol. 28:3–5. 2010. View Article : Google Scholar : PubMed/NCBI
24	Zhu CQ, Ding K, Strumpf F, Weir BA, Meyerson M, Pennell N, Thomas RK, Naoki K, Ladd-Acosta C, Liu N, Pintilie M, Der S, et al: Prognostic and predictive gene signature for adjuvant chemotherapy in resected non-small-cell lung cancer. J Clin Oncol. 28:4417–4424. 2010. View Article : Google Scholar : PubMed/NCBI
25	Xie Y and Minna JD: Non-small-cell lung cancer mRNA expression signature predicting response to adjuvant chemotherapy. J Clin Oncol. 28:4404–4407. 2010. View Article : Google Scholar : PubMed/NCBI